IBTK and mantle cell lymphoma: A recent study demonstrated that metabolic reprogramming-mediated glutaminolysis was associated with Bruton’s tyrosine kinase inhibitor (BTKi) resistance in mantle cell lymphoma (MCL) [15], suggesting the promise of targeting metabolism in hematological tumors.